Alembic Pharma gets USFDA nod for antihypertensive tablets

Drug firm Alembic Pharmaceuticals today said it has received approval from the US health regulator for generic Olmesartan Medoxomil and Amlodipine tablets used for the treatment of hypertension.

The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Olmesartan Medoxomil and Amlodipine tablets, Alembic Pharmaceuticals said in a BSE filing.

The approval is for the tablets in the strengths of 20mg/5mg, 40 mg/5 mg, 20 mg/10 mg and 40 mg/10 mg, it added.

The product is generic version of Daiichi Sankyo Inc's Azor tablets in the same strengths, Alembic Pharma said.

The tablets are indicated for the treatment of hypertension, alone or with antihypertensive agents to lower blood pressure, it added.

According to IMS the Olmesartan Medoxomil and Amlodipine tablets had an estimated market size of USD 312 million for twelve months ending December 2016.

The company has a total of 61 ANDA approvals from the USFDA.

Shares of Alembic Pharmaceuticals today closed 1.75 per cent up at Rs 554.95 per scrip on BSE.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)